Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 23


Cytotoxic and targeted therapy for hereditary cancers.

Iyevleva AG, Imyanitov EN.

Hered Cancer Clin Pract. 2016 Aug 23;14(1):17. doi: 10.1186/s13053-016-0057-2. Review.


Lymphatic Vessels, Inflammation, and Immunity in Skin Cancer.

Lund AW, Medler TR, Leachman SA, Coussens LM.

Cancer Discov. 2016 Jan;6(1):22-35. doi: 10.1158/2159-8290.CD-15-0023. Review.


Shh and p50/Bcl3 signaling crosstalk drives pathogenesis of BCCs in Gorlin syndrome.

Chaudhary SC, Tang X, Arumugam A, Li C, Srivastava RK, Weng Z, Xu J, Zhang X, Kim AL, McKay K, Elmets CA, Kopelovich L, Bickers DR, Athar M.

Oncotarget. 2015 Nov 3;6(34):36789-814. doi: 10.18632/oncotarget.5103.


Silibinin and its 2,3-dehydro-derivative inhibit basal cell carcinoma growth via suppression of mitogenic signaling and transcription factors activation.

Tilley C, Deep G, Agarwal C, Wempe MF, Biedermann D, Valentov√° K, Kren V, Agarwal R.

Mol Carcinog. 2016 Jan;55(1):3-14. doi: 10.1002/mc.22253.


Sonic hedgehog signaling in Basal cell nevus syndrome.

Athar M, Li C, Kim AL, Spiegelman VS, Bickers DR.

Cancer Res. 2014 Sep 15;74(18):4967-75. doi: 10.1158/0008-5472.CAN-14-1666. Review.


Cyclooxygenases: mediators of UV-induced skin cancer and potential targets for prevention.

Elmets CA, Ledet JJ, Athar M.

J Invest Dermatol. 2014 Oct;134(10):2497-502. doi: 10.1038/jid.2014.192. Review.


Nitric oxide-releasing sulindac is a novel skin cancer chemopreventive agent for UVB-induced photocarcinogenesis.

Chaudhary SC, Singh T, Kapur P, Weng Z, Arumugam A, Elmets CA, Kopelovich L, Athar M.

Toxicol Appl Pharmacol. 2013 May 1;268(3):249-55. doi: 10.1016/j.taap.2012.12.009.


Patched knockout mouse models of Basal cell carcinoma.

Nitzki F, Becker M, Frommhold A, Schulz-Schaeffer W, Hahn H.

J Skin Cancer. 2012;2012:907543.


Genetic ablation of cyclooxygenase-2 in keratinocytes produces a cell-autonomous defect in tumor formation.

Lao HC, Akunda JK, Chun KS, Flake GP, Yuspa SH, Langenbach R.

Carcinogenesis. 2012 Nov;33(11):2293-300. doi: 10.1093/carcin/bgs267.


Nanoelectroablation therapy for murine basal cell carcinoma.

Nuccitelli R, Tran K, Athos B, Kreis M, Nuccitelli P, Chang KS, Epstein EH Jr, Tang JY.

Biochem Biophys Res Commun. 2012 Aug 3;424(3):446-50. doi: 10.1016/j.bbrc.2012.06.129.


Non-steroidal anti-inflammatory drugs, acetaminophen, and risk of skin cancer in the Nurses' Health Study.

Jeter JM, Han J, Martinez ME, Alberts DS, Qureshi AA, Feskanich D.

Cancer Causes Control. 2012 Sep;23(9):1451-61. doi: 10.1007/s10552-012-0019-6.


Use of nonsteroidal anti-inflammatory drugs and risk of basal cell carcinoma in the United States Radiologic Technologists study.

Cahoon EK, Rajaraman P, Alexander BH, Doody MM, Linet MS, Freedman DM.

Int J Cancer. 2012 Jun 15;130(12):2939-48. doi: 10.1002/ijc.26286.


Targeting superficial or nodular Basal cell carcinoma with topically formulated small molecule inhibitor of smoothened.

Tang T, Tang JY, Li D, Reich M, Callahan CA, Fu L, Yauch RL, Wang F, Kotkow K, Chang KS, Shpall E, Wu A, Rubin LL, Marsters JC Jr, Epstein EH Jr, Caro I, de Sauvage FJ.

Clin Cancer Res. 2011 May 15;17(10):3378-87. doi: 10.1158/1078-0432.CCR-10-3370.


New agents for prevention of ultraviolet-induced nonmelanoma skin cancer.

Camp WL, Turnham JW, Athar M, Elmets CA.

Semin Cutan Med Surg. 2011 Mar;30(1):6-13. doi: 10.1016/j.sder.2011.01.003.


Chemoprevention of nonmelanoma skin cancer with celecoxib: a randomized, double-blind, placebo-controlled trial.

Elmets CA, Viner JL, Pentland AP, Cantrell W, Lin HY, Bailey H, Kang S, Linden KG, Heffernan M, Duvic M, Richmond E, Elewski BE, Umar A, Bell W, Gordon GB.

J Natl Cancer Inst. 2010 Dec 15;102(24):1835-44. doi: 10.1093/jnci/djq442.


High prevalence of vitamin D deficiency in patients with basal cell nevus syndrome.

Tang JY, Wu A, Linos E, Parimi N, Lee W, Aszterbaum M, Asgari MM, Bickers DR, Epstein EH Jr.

Arch Dermatol. 2010 Oct;146(10):1105-10. doi: 10.1001/archdermatol.2010.247.


Hereditary genodermatoses with cancer predisposition.

Gerstenblith MR, Goldstein AM, Tucker MA.

Hematol Oncol Clin North Am. 2010 Oct;24(5):885-906. doi: 10.1016/j.hoc.2010.06.003. Review.


Changes in skin cancer management : a personal perspective.

Naylor M.

J Clin Aesthet Dermatol. 2010 Apr;3(4):16-9. No abstract available.

Items per page

Supplemental Content

Support Center